Translating Scientific Advances In Inner Ear Biology Into Novel Therapies For People With Hearing Disorders


Decibel Therapeutics is a hearing company focused on discovering and developing new therapies to protect, repair and restore hearing. By combining recent innovations in hearing science with leading diagnostic tools, biological insights, modeling and therapeutic delivery techniques, Decibel is pioneering a comprehensive approach to define the underlying biological causes of hearing loss and develop a pipeline of breakthrough therapies targeted to specific indications and populations. 


Year Invested: 2015
Location: Cambridge, Mass.
Visit: www.decibeltx.com

Recent News

September 27, 2018
Decibel Therapeutics and Oricula Therapeutics Announce Exclusive License for ORC-13661 in Phase 1 Development for Hearing and Balance Protection

August 2, 2018
Decibel Therapeutics Research on The Role of Molecular Diversity in Neurons Critical for Hearing Published in Cell

June 19, 2018
Decibel Therapeutics Closes $55 Million Series C Financing

Read More News

Associated Team Members

Kevin Starr
Partner

Craig Muir
Partner/Chief Technology Officer